Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00.

A patient receiving physical therapy for a neurological disease.

The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while GAAP diluted EPS for the quarter reached $1.64. Product revenue also rose 3%  year-over-year at constant currency and 1% year-over-year at actual currency.

Management is optimistic due to the transformation in the company’s portfolio, with approximately 45% of the total product revenue in the quarter coming from significant medicines outside Biogen Inc.’s (NASDAQ:BIIB) MS business.

Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases worldwide. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).

While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.